Zuplenz

Pruritus, Hyperemesis Gravidarum, Nausea + 8 more

Treatment

4 Active Studies for Zuplenz

What is Zuplenz

Ondansetron

The Generic name of this drug

Treatment Summary

Ondansetron is a drug used to reduce nausea and vomiting caused by chemotherapy. It has also been shown to have anti-anxiety and anti-psychotic properties. It was developed in the 1980s by GlaxoSmithKline and approved by the US FDA in 1991. It is available in the form of oral tablets, orally dissolving tablets, injections, and generic products. Recently, orally soluble films have also been developed which make it easier for patients to take the drug during vomiting.

Zofran

is the brand name

Zuplenz Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zofran

Ondansetron

1991

583

Effectiveness

How Zuplenz Affects Patients

Ondansetron is a drug used to treat nausea and vomiting caused by chemotherapy. It works by blocking serotonin receptors that are located in the nerve endings of the vagus nerve, as well as the area postrema in the brain. These receptors help to trigger the vomiting reflex and cause nausea. Ondansetron has been found to prolong the QTc interval, which is a measure of the time between heartbeats, but this effect is only seen in high doses given intravenously. No ECG assessment study has been done for orally administered ondansetron and the effects of the recommended dose for children have

How Zuplenz works in the body

Ondansetron works by blocking a nerve reflex that causes you to vomit. This reflex is triggered when a chemical called serotonin is released in response to treatment like chemotherapy or radiation. Ondansetron targets the receptors that serotonin binds to, which stops the reflex and prevents vomiting. This effect has been seen in cases of postoperative nausea and vomiting, as well as chemotherapy-induced nausea and vomiting. The exact mechanism of how it works in cases of opiate-induced emesis is not yet known.

When to interrupt dosage

The suggested dosage of Zuplenz is contingent upon the diagnosed condition, such as Uremia, radiation therapy induced nausea and vomiting and Pharmacotherapy. The measure of dosage fluctuates as per the method of administration noted in the table beneath.

Condition

Dosage

Administration

Pharmacotherapy

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Nausea

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Uremia

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Pharmacotherapy

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Malignant Neoplasms

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Pruritus

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Hyperemesis Gravidarum

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Nausea

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

radiation therapy induced nausea and vomiting

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Nausea

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Malignant Neoplasms

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Warnings

Zuplenz has one contraindication and should not be consumed in combination with the circumstances detailed in the following table.

Zuplenz Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Zuplenz.

Common Zuplenz Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Ondansetron.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Ondansetron.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Anagrelide.

Apomorphine

Major

The risk or severity of adverse effects can be increased when Ondansetron is combined with Apomorphine.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Arsenic trioxide.

Zuplenz Toxicity & Overdose Risk

Taking too much ondansetron can lead to unusual side effects, including temporary blindness, low blood pressure, constipation, neuromuscular issues, drowsiness, and seizures. All of these symptoms have been resolved in the instances reported. Ondansetron is not recommended for use during pregnancy and it is unknown if it is excreted in breast milk, so nursing is not advised while taking this medication. There is not enough information available to provide dosage recommendations for children who are 3 years old or younger.

image of a doctor in a lab doing drug, clinical research

Zuplenz Novel Uses: Which Conditions Have a Clinical Trial Featuring Zuplenz?

Currently, two clinical trials are investigating the use of Zuplenz to alleviate Nausea, Uremia and radiation-induced Nausea and Vomiting.

Condition

Clinical Trials

Trial Phases

Hyperemesis Gravidarum

0 Actively Recruiting

Nausea

0 Actively Recruiting

radiation therapy induced nausea and vomiting

0 Actively Recruiting

Malignant Neoplasms

0 Actively Recruiting

Nausea

3 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Nausea

0 Actively Recruiting

Pruritus

0 Actively Recruiting

Pharmacotherapy

0 Actively Recruiting

Uremia

0 Actively Recruiting

Pharmacotherapy

1 Actively Recruiting

Not Applicable

Malignant Neoplasms

0 Actively Recruiting

Zuplenz Reviews: What are patients saying about Zuplenz?

5

Patient Review

4/21/2015

Zuplenz for Prevent Nausea and Vomiting from Cancer Chemotherapy

I'm glad I don't have to swallow a pill for this treatment!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zuplenz

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Zuplenz used for?

"This medication is used to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy), radiation treatment, or drugs used to put you to sleep before surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting."

Answered by AI

What is ondansetron mainly used for?

"Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting."

Answered by AI

How do you take Zuplenz?

"The patient should place the film on top of his tongue, where it will dissolve within 4 to 20 seconds. Once it has dissolved, the patient can swallow liquid if he wishes, but it is not required. The patient should wash his hands after taking ZUPLENZ."

Answered by AI

How much does Zuplenz cost?

"Zuplenz oral disintegrating strips cost around $1,127 for a supply of 30, depending on the pharmacy you visit."

Answered by AI

Clinical Trials for Zuplenz

Image of Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Canada.

Aprepitant for Postoperative Nausea and Vomiting

18+
All Sexes
Montreal, Canada

Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.

Phase 3
Waitlist Available

Centre hospitalier de l'Université de Montréal (CHUM)

Maxim Roy, MD, FRCPC

Image of Endeavor Health in Evanston, United States.

Autonomic Neural Blockade for Postoperative Symptoms in Bariatric Surgery

18 - 90
All Sexes
Evanston, IL

The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain/nausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.

Waitlist Available
Has No Placebo

Endeavor Health

Herbert Hedberg, MD

Image of The Hospital for Sick Children in Toronto, Canada.

ML-Based Intervention for Vomiting in Pediatric Cancer

Any Age
All Sexes
Toronto, Canada

The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients. The main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will: Primary 1\. Reduce the proportion with any vomiting within the 96-hour window Secondary 1. Reduce the number of vomiting episodes 2. Increase the proportion receiving care pathway-consistent care 3. Impact on number of administrations and costs of antiemetic medications Newly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.

Recruiting
Has No Placebo

The Hospital for Sick Children

Santiago Arciniegas, MSc